MPPE1 and Hyperglycemia: In vivo, daily 2-DG treatment of IAV-infected mice led to transient hyperglycaemia after each injection (Extended Data Fig. 10v), impaired survival (Extended Data Fig. 11a), delayed viral clearance (Extended Data Fig. 11b), impaired adaptive immunity (Extended Data Fig. 11c–h) and reduced lung cDC1 (Extended Data Fig. 11i–k).